4D Molecular Therapeutics, Inc. (FDMT) Tops Q2 EPS by 1c
Tweet
Share
E-mailGet Alerts FDMT Hot Sheet
Join SI Premium – FREE
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($0.77), $0.01 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $848.33 thousand.
For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Albertsons (ACI) Misses Q1 EPS by 12c; offers guidance
- Freeport-McMoran (FCX) Tops Q2 EPS by 15c
- Arrow Financial (AROW) Misses Q2 EPS by 14c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
